Organoids: Synthetic scaffolds help airway cells reach maturity
The human airways bring air into and out of the lungs, and the epithelium that lines these airways uses a combination of mucus and hair-like structures called cilia to clear inhaled particles and microorganisms from the lungs. For decades cell biologists have been able to make mature airway epithelia in vitro by taking airway cells from patients and cadavers and growing them in culture. These epithelia have been used for a range of applications, from fundamental cell biology and cancer genetics to clinical diagnosis and pharmacological testing (discussed in Fulcher et al., 2005). In recent years researchers have been trying to use human pluripotent stem cells – cells that can differentiate to become any of the types of cells that are found in the body – to make mature airway epithelia. However, if such epithelia are available from real people, potentially with a complete medical history, why is there any interest in using pluripotent stem cells to make them?
The answer is two-fold. First, the adult epithelia grown in culture suffer from various limitations: they are highly variable, they contain only a limited range of cell types, and it is not possible to introduce targeted genetic mutations in them, although numerous labs are working to solve these issues (Mou et al., 2016; Butler et al., 2016). Second, the use of pluripotent stem cells to make mature airway epithelia has the attraction of allowing researchers to study the progressive development of a disease over time. In addition, the use of pluripotent stem cell lines will make it possible to introduce a specific genetic alteration and study its effect by comparing these cell lines to otherwise genetically identical control cells. Reproducible growth of epithelia with these features has the potential to improve disease modeling, to facilitate drug discovery across a range of lung diseases, and to provide a limitless supply of cells for toxicology testing, or even for regenerative medicine. However, while there have been numerous reports of methods for producing mature airway epithelia from pluripotent stem cells, the cells in these epithelia have tended to resemble embryonic and neonatal cells rather than mature adult cells.
The airways and lungs are derived from a region in the developing embryo called the anterior foregut endoderm. A typical method for making mature epithelia from stem cells involves starting with pluripotent stem cells and coaxing them to become endoderm cells, then anterior foregut endoderm cells, then lung progenitor cells (which can become any type of lung cell) and, finally, various types of airway epithelial cells. One recent innovation involved the growth of three-dimensional structures called human lung organoids by a group at the University of Michigan (Dye et al., 2015) and another group at Kyoto Univerisity and Osaka University (Konishu et al., 2016). These organoids contained many of the cell types that are found in mature airway epithelia but, notably, they did not contain mature goblet cells (the cells that produce mucus) or a number of other secretory cells (Figure 1A). Now, building on their previous work, Jason Spence of the University of Michigan and co-workers – including Briana Dye as first author – report that these shortcomings can be overcome by using a combination of synthetic "scaffolds" and in vivo growth in mice (Dye et al., 2016).
It has become a standard technique to implant immature organoids (or cells derived from pluripotent stem cells) into well-vascularized sites in mice whose immune system has been compromised. The growth of the cells in this in vivo environment, typically in the kidney capsule or in fatty tissue adjacent to the stomach or epididymis, helps them to mature properly, presumably due to the physiological levels of nutrients, oxygen and circulating factors. Dye et al. started by taking human lung organoids that had been grown in a basement membrane substrate (Matrigel) and implanting them directly into the mice. Although human epithelia were recovered from these initial transplants, they rarely contained lung cells.
In an attempt to solve this problem Dye et al. decided to first culture the organoids on synthetic scaffolds made of a polymer called Poly(lactide-co-glycolide), which is used in medical devices and for culturing pancreatic cells (Yap et al., 2013). Given the size of the scaffolds, the only suitable transplantation site was the fat pad adjacent to the epididymis (which is near the testicles in male mice). When the scaffolds were retrieved from the mice, typically following 8–15 weeks of growth in vivo, the organoids had frequently grown into tubes that resembled the adult airway and, moreover, they contained a wider range of mature cell types than had been produced before (Figure 1B). Importantly, this latter finding was validated by detailed comparison to human fetal and adult airways.
The in vivo system developed by Dye, Spence and co-workers appears to be reproducible across multiple pluripotent cell lines and could be used to develop improved models of adult lung diseases and for pre-clinical drug testing. And if we can learn more about the mechanisms that underlie the maturation process, it might be possible to produce mature epithelia in vitro for high-throughput (drug discovery-type) experiments. It will also be important to assess whether mature alveoli (the lung cells that are involved in the exchange of oxygen and carbon dioxide) can be generated from pluripotent stem cells through similar in vivo transplantation approaches. Further study is also needed to assess how different types of scaffolds affect the maturation of cells in vivo.
References
-
Rapid expansion of human epithelial stem cells suitable for airway tissue engineeringAmerican Journal of Respiratory and Critical Care Medicine 194:156–168.https://doi.org/10.1164/rccm.201507-1414OC
-
Well-differentiated human airway epithelial cell culturesMethods in Molecular Medicine 107:183–206.https://doi.org/10.1385/1-59259-861-7:183
-
Collagen IV-modified scaffolds improve islet survival and function and reduce time to euglycemiaTissue Engineering Part A 19:2361–2372.https://doi.org/10.1089/ten.tea.2013.0033
Article and author information
Author details
Publication history
Copyright
© 2016, Nikolić et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,444
- views
-
- 201
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Genetics and Genomics
- Stem Cells and Regenerative Medicine
Retinal degeneration in mammals causes permanent loss of vision, due to an inability to regenerate naturally. Some non-mammalian vertebrates show robust regeneration, via Muller glia (MG). We have recently made significant progress in stimulating adult mouse MG to regenerate functional neurons by transgenic expression of the proneural transcription factor Ascl1. While these results showed that MG can serve as an endogenous source of neuronal replacement, the efficacy of this process is limited. With the goal of improving this in mammals, we designed a small molecule screen using sci-Plex, a method to multiplex up to thousands of single-nucleus RNA-seq conditions into a single experiment. We used this technology to screen a library of 92 compounds, identified, and validated two that promote neurogenesis in vivo. Our results demonstrate that high-throughput single-cell molecular profiling can substantially improve the discovery process for molecules and pathways that can stimulate neural regeneration and further demonstrate the potential for this approach to restore vision in patients with retinal disease.
-
- Stem Cells and Regenerative Medicine
Adult mammals, unlike some lower organisms, lack the ability to regenerate damaged hearts through cardiomyocytes (CMs) dedifferentiation into cells with regenerative capacity. Developing conditions to induce such naturally unavailable cells with potential to proliferate and differentiate into CMs, that is, regenerative cardiac cells (RCCs), in mammals will provide new insights and tools for heart regeneration research. In this study, we demonstrate that a two-compound combination, CHIR99021 and A-485 (2C), effectively induces RCCs from human embryonic stem cell-derived TNNT2+ CMs in vitro, as evidenced by lineage tracing experiments. Functional analysis shows that these RCCs express a broad spectrum of cardiogenesis genes and have the potential to differentiate into functional CMs, endothelial cells, and smooth muscle cells. Importantly, similar results were observed in neonatal rat CMs both in vitro and in vivo. Remarkably, administering 2C in adult mouse hearts significantly enhances survival and improves heart function post-myocardial infarction. Mechanistically, CHIR99021 is crucial for the transcriptional and epigenetic activation of genes essential for RCC development, while A-485 primarily suppresses H3K27Ac and particularly H3K9Ac in CMs. Their synergistic effect enhances these modifications on RCC genes, facilitating the transition from CMs to RCCs. Therefore, our findings demonstrate the feasibility and reveal the mechanisms of pharmacological induction of RCCs from endogenous CMs, which could offer a promising regenerative strategy to repair injured hearts.